← All trials
NCT06438978
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 19, 2024
- Primary completion
- Jan 29, 2024
- Completion date
- Aug 31, 2024
- First posted
- Jun 3, 2024
- Last posted
- Jun 3, 2024
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bharat Biotech International LimitedLead sponsor
- Bharat Biotech International LimitedOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.